Cancer Chemotherapy and Pharmacology

, Volume 59, Issue 5, pp 637–642

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

  • Emilio Bajetta
  • Laura Catena
  • Giuseppe Procopio
  • Sara De Dosso
  • Ettore Bichisao
  • Leonardo Ferrari
  • Antonia Martinetti
  • Marco Platania
  • Elena Verzoni
  • Barbara Formisano
  • Roberto Bajetta
Original Article

Abstract

Purpose

The aim of this trial was to evaluate the safety and efficacy of oxaliplatin and capecitabine (XELOX) in neuroendocrine tumours’ (NETs) treatment.

Methods

Forty patients (pts) with advanced NETs were treated. Of these, 13 had untreated poorly differentiated NETs, 27 had well-differentiated NETs in progression after somatostatin analogues. Patients received oxaliplatin e.v. 130 mg/mq i.v. and capecitabine 2,000 mg/mq/die. The primary sites of the disease were: lung (10 pts), pancreas (15 pts), small bowel (8 pts), unknown (1 pt), others (6 pts).

Results

In 13 pts with poorly differentiated NETs objective responses (OR) were: 3 PR (23%), 1 SD (7%), 9 PD (70%). Biochemical responses were 11%. In 27 patients with well-differentiated NETs the OR were: 8 PR (30%), 13 SD (48%) and 6 PD (22%). Biochemical and symptomatic responses were 20 and 50%, respectively.

Conclusions

The XELOX regimen is effective and tolerated in well-differentiated NETs after progression following somatostatin analogues.

Keywords

Capecitabine Chemotherapy Neuroendocrine tumours Oxaliplatin XELOX 

References

  1. 1.
    Solcia E, Kloppel G, Sobin LH (2000) Histologic typing of endocrine tumours. WHO international histological classification of tumours. Springer, Berlin Heidelberg New YorkGoogle Scholar
  2. 2.
    Travis WD, Brambilla E, Muller-Hermelink HK, Harris SL (2004) Pathology and genetics of tumors of the lung, pleura, thymus and heart. IARC Press, GenevaGoogle Scholar
  3. 3.
    Bajetta E, Catena L, Procopio G, Bichisao E, Ferrari L, Della Torre S, De Dosso S, Iacobelli S, Buzzoni R, Mariani L, Rosai J (2005) Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann Oncol 16:1374–1380PubMedCrossRefGoogle Scholar
  4. 4.
    Artale S, Giannetta L, Cerea G, Pedrazzoli P, Schiavetto I, Napolitano M, Veronese S, Bramerio E, Gambacorta M, Vanzulli A, Pisconti S, Pugliese R, Siena S (2005) Treatment of metastatic neuroendocrine carcinomas based on WHO classification. Anticancer Res 25:4463–4469PubMedGoogle Scholar
  5. 5.
    Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in anaplastic variance of these neoplasm. Cancer 68:227–232PubMedCrossRefGoogle Scholar
  6. 6.
    Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK (2001) Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92:1101–1107PubMedCrossRefGoogle Scholar
  7. 7.
    Rivera E, Ajani JA (1998) Doxorubicin, streptozotocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin 21:36–38CrossRefGoogle Scholar
  8. 8.
    Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin–doxorubicin, streptozocin–fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523PubMedCrossRefGoogle Scholar
  9. 9.
    Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, Di Bartolomeo M, Buzzoni R, Celio L, Vitali M, Beretta E, Seregni E, Bombardieri E (2002) Efficacy of chemotherapy combinations for the treatment of metastatic neuroendocrine tumours. Ann Oncol 13:614–621PubMedCrossRefGoogle Scholar
  10. 10.
    Ridolfi R, Amaducci L, Derni S, Fabbri L, Innocenti MP, Vignutelli P (1991) Chemotherapy with 5-fluorouracil and streptozocin in carcinoid tumors of gastrointestinal origin: experiences with 13 patients. J Chemother 3:328–331PubMedGoogle Scholar
  11. 11.
    Gonzalez MA, Biswas S, Clifton L, Corrie PG (2003) Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin. Br J Cancer 89:455–456PubMedCrossRefGoogle Scholar
  12. 12.
    Bajetta E, Zilembo N, Di Bartolomeo M, Di Leo A, Pilotti S, Bochicchio AM, Castellani R, Buzzoni R, Celio L, Dogliotti L (1993) Treatment of metastatic carcinoid and other neuroendocrine tumors with recombinant interferon alpha-2. Cancer 72:3099–3105PubMedCrossRefGoogle Scholar
  13. 13.
    Tetzlaff ED, Ajani JA (2005) Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor. Int J Gastrointest Cancer 36:55–58PubMedCrossRefGoogle Scholar
  14. 14.
    World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO offset publication N. 48, GenevaGoogle Scholar
  15. 15.
    Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81:1351–1355PubMedCrossRefGoogle Scholar
  16. 16.
    Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in anaplastic variance of these neoplasm. Cancer 68:227–232PubMedCrossRefGoogle Scholar
  17. 17.
    Oberg K (2001) Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 12(Suppl 2):S111–S114PubMedCrossRefGoogle Scholar
  18. 18.
    Rougier P, Mitry E (2000) Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 62:73–78PubMedCrossRefGoogle Scholar
  19. 19.
    Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG (2005) Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281. J Clin Oncol 22:4897–4904CrossRefGoogle Scholar
  20. 20.
    Di Bartolomeo M, Bajetta E, Bochicchio AM, Carnaghi C, Somma L, Mazzaferro V, Visini M, Gebbia V, Tumolo S, Ballatore P (1995) A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) group. Ann Oncol 6:77–79PubMedGoogle Scholar
  21. 21.
    Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401–406PubMedCrossRefGoogle Scholar
  22. 22.
    Pavel ME, Baum U, Hahn EG, Hensen J (2005) Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors. Int J Gastrointest Cancer 35:179–185PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Emilio Bajetta
    • 1
  • Laura Catena
    • 1
  • Giuseppe Procopio
    • 1
  • Sara De Dosso
    • 1
  • Ettore Bichisao
    • 2
  • Leonardo Ferrari
    • 1
  • Antonia Martinetti
    • 1
  • Marco Platania
    • 1
  • Elena Verzoni
    • 1
  • Barbara Formisano
    • 1
  • Roberto Bajetta
    • 3
  1. 1.S.C. Oncologia Medica 2Istituto Nazionale per lo Studio e la Cura dei TumoriMilanItaly
  2. 2.I.T.M.O. GroupMilanItaly
  3. 3.Pharmacology UnitIstituto Nazionale per lo Studio e la Cura dei TumoriMilanItaly

Personalised recommendations